메뉴 건너뛰기




Volumn 47, Issue 1, 2012, Pages 15-22

Linaclotide: A guanylate cyclase type-C agonist for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation

Author keywords

[No Author keywords available]

Indexed keywords

GUANYLATE CYCLASE ACTIVATOR; LINACLOTIDE;

EID: 84856865386     PISSN: 1082801X     EISSN: 19381166     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (2)

References (27)
  • 1
    • 67649537590 scopus 로고    scopus 로고
    • An evidence-based systematic review on the management of irritable bowel syndrome
    • Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(suppl 1):S1-S35.
    • (2009) Am J Gastroenterol , vol.104 , Issue.SUPPL. 1
    • Brandt, L.J.1    Chey, W.D.2    Foxx-Orenstein, A.E.3
  • 2
    • 84856828482 scopus 로고    scopus 로고
    • Diarrhea, constipation, and irritable bowel syndrome
    • DiPiro J T, Talbert RL, Yee GC, et al, 8th ed. New York, NY: McGraw Hill, Accessed December 3, 2011
    • Powell PH, Fleming VH. Diarrhea, constipation, and irritable bowel syndrome. In: DiPiro J T, Talbert RL, Yee GC, et al. Pharmacother-apy: A Pathophysiologic Approach. 8th ed. New York, NY: McGraw Hill; 2011. Available at http://www.accesspharmacy.com/content.aspx?aID=7978775. Accessed December 3, 2011.
    • (2011) Pharmacother-apy: A Pathophysiologic Approach
    • Powell, P.H.1    Fleming, V.H.2
  • 3
    • 0141653832 scopus 로고    scopus 로고
    • Chronic constipation
    • Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003;349(14):1360-1368.
    • (2003) N Engl J Med , vol.349 , Issue.14 , pp. 1360-1368
    • Lembo, A.1    Camilleri, M.2
  • 4
    • 0034464011 scopus 로고    scopus 로고
    • American Gastroenterological Association medical position statement: Guidelines on constipation
    • Locke GR III, Pemberton JH, Phillips SF. American Gastroenterological Association medical position statement: guidelines on constipation. Gastroenterology. 2000;119:1761-1766.
    • (2000) Gastroenterology , vol.119 , pp. 1761-1766
    • Locke, G.R.1    Pemberton, J.H.2    Phillips, S.F.3
  • 5
    • 78650743393 scopus 로고    scopus 로고
    • Lubiprostone: Evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome
    • Lunsford TN, Harris LA. Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. Int J Womens Health. 2010;2:361-374.
    • (2010) Int J Womens Health , vol.2 , pp. 361-374
    • Lunsford, T.N.1    Harris, L.A.2
  • 6
    • 77449106445 scopus 로고    scopus 로고
    • Methylnaltrexone: A subcutaneous treatment for opioid-induced constipation in palliative care patients
    • Kyle G. Methylnaltrexone: a subcutaneous treatment for opioid-induced constipation in palliative care patients. Int J Palliat Nurs. 2009;15(11):533-540.
    • (2009) Int J Palliat Nurs , vol.15 , Issue.11 , pp. 533-540
    • Kyle, G.1
  • 7
    • 0036792345 scopus 로고    scopus 로고
    • Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome
    • Tougas G, Snape WJ, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2002;16(10):1701-1708.
    • (2002) Aliment Pharmacol Ther , vol.16 , Issue.10 , pp. 1701-1708
    • Tougas, G.1    Snape, W.J.2    Otten, M.H.3
  • 8
    • 79959789162 scopus 로고    scopus 로고
    • FDA, Accessed December 3, 2011
    • FDA. Public health advisory: tegaserod ma-leate (marketed as Zelnorm); March 30, 2007. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfor-mationforPatientsandProviders/DrugSafe-tyInformationforHealthcareProfessionals/ PublicHealthAdvisories/ucm051284.htm. Accessed December 3, 2011.
    • (2007) Public Health Advisory: Tegaserod Ma-leate (marketed As Zelnorm)
  • 9
    • 41949139816 scopus 로고    scopus 로고
    • FDA, press release, Accessed December 3, 2011
    • FDA. FDA permits restricted use of Zelnorm for qualifying patients [press release]; July 27, 2007. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce-ments/2007/ucm108956.htm. Accessed December 3, 2011.
    • (2007) FDA Permits Restricted Use of Zelnorm For Qualifying Patients
  • 11
    • 84856833434 scopus 로고    scopus 로고
    • Amitiza [prescribing information]. Bethesda, MD: Sucampo Pharma Americas, Inc
    • Amitiza [prescribing information]. Bethesda, MD: Sucampo Pharma Americas, Inc, 2011.
    • (2011)
  • 13
    • 78049283798 scopus 로고    scopus 로고
    • Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit
    • Busby RW, Bryant A P, Bartolini W P, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol. 2010;649:328-335.
    • (2010) Eur J Pharmacol , vol.649 , pp. 328-335
    • Busby, R.W.1    Bryant, A.P.2    Bartolini, W.P.3
  • 14
    • 77951897011 scopus 로고    scopus 로고
    • Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract
    • Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010;86:760-765.
    • (2010) Life Sci , vol.86 , pp. 760-765
    • Bryant, A.P.1    Busby, R.W.2    Bartolini, W.P.3
  • 15
    • 71649115806 scopus 로고    scopus 로고
    • Oral cyclic guanosine monophosphate (cGMP) desensitizes colonic afferents in an animal model of experimental colitis [abstract 486]
    • Ustinova E, Bryant A, Rez T, et al. Oral cyclic guanosine monophosphate (cGMP) desensitizes colonic afferents in an animal model of experimental colitis [abstract 486]. Am J Gas-troenterol. 2008(suppl 1);103:S187.
    • (2008) Am J Gas-troenterol , vol.103 , Issue.SUPPL. 1
    • Ustinova, E.1    Bryant, A.2    Rez, T.3
  • 16
    • 83155177478 scopus 로고    scopus 로고
    • Rat intestinal metabolism of linaclotide, a therapeutic agent in clinical development for the treatment of IBS-C and chronic constipation [abstract 292]
    • Kessler MM, Busby RW, Wakefleld JD, et al. Rat intestinal metabolism of linaclotide, a therapeutic agent in clinical development for the treatment of IBS-C and chronic constipation [abstract 292]. Drug Metab Rev. 2008;40(suppl 3):213-214.
    • (2008) Drug Metab Rev , vol.40 , Issue.SUPPL. 3 , pp. 213-214
    • Kessler, M.M.1    Busby, R.W.2    Wakefleld, J.D.3
  • 17
    • 83155182931 scopus 로고    scopus 로고
    • Linaclotide: A novel approach to the treatment of irritable bowel syndrome
    • Wensel TM, Luthin DR. Linaclotide: a novel approach to the treatment of irritable bowel syndrome. Ann Pharmacother. 2011 Dec;45(12):1535-1543.
    • (2011) Ann Pharmacother , vol.45 , Issue.12 , pp. 1535-1543
    • Wensel, T.M.1    Luthin, D.R.2
  • 18
    • 83155185785 scopus 로고    scopus 로고
    • Efficacy and safety of once-daily linaclotide administered orally for 26 weeks in patients with IBS-C: Results from a randomized, double-blind, placebo-controlled phase 3 trial [AGA abstract 837]
    • Chey WD, Lembo A, MacDougall JE, et al. Efficacy and safety of once-daily linaclotide administered orally for 26 weeks in patients with IBS-C: results from a randomized, double-blind, placebo-controlled phase 3 trial [AGA abstract 837]. Gastroenterology. 2011(suppl);140:S135.
    • (2011) Gastroenterology , vol.140 , Issue.SUPPL.
    • Chey, W.D.1    Lembo, A.2    Macdougall, J.E.3
  • 19
    • 82955175836 scopus 로고    scopus 로고
    • Efficacy and safety of once daily linaclotide in patients with irritable bowel syndrome with constipation: A 12-week, randomized, double-blind, placebo-controlled phase 3 trial followed by a 4-week randomized withdrawal period [AGA abstract 845]
    • Rao S, Lembo A, Shiff SJ, et al. Efficacy and safety of once daily linaclotide in patients with irritable bowel syndrome with constipation: a 12-week, randomized, double-blind, placebo-controlled phase 3 trial followed by a 4-week randomized withdrawal period [AGA abstract 845]. Gastroenterology. 2011(suppl):140:S138.
    • (2011) Gastroenterology , vol.140 , Issue.SUPPL.
    • Rao, S.1    Lembo, A.2    Shiff, S.J.3
  • 20
    • 80051640525 scopus 로고    scopus 로고
    • Two randomized trials of linaclotide for chronic constipation
    • Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365:527-536.
    • (2011) N Engl J Med , vol.365 , pp. 527-536
    • Lembo, A.J.1    Schneier, H.A.2    Shiff, S.J.3
  • 21
    • 83155177485 scopus 로고    scopus 로고
    • Effect of linaclotide on quality of life in adults wih irritable bowel syndrome with constipation: Pooled results from two randomized, double-blind, placebo-controlled phase 3 trials [AGA abstract 223]
    • Carson R, Tourkodimitris S, Lewis BE, et al. Effect of linaclotide on quality of life in adults wih irritable bowel syndrome with constipation: pooled results from two randomized, double-blind, placebo-controlled phase 3 trials [AGA abstract 223]. Gastroenterology. 2011(suppl);140:S51.
    • (2011) Gastroenterology , vol.140 , Issue.SUPPL.
    • Carson, R.1    Tourkodimitris, S.2    Lewis, B.E.3
  • 23
    • 77249122338 scopus 로고    scopus 로고
    • Efficacy of linaclotide for patients with chronic constipation
    • Lembo AJ, Kurtz CB, MacDougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138:886-895.
    • (2010) Gastroenterology , vol.138 , pp. 886-895
    • Lembo, A.J.1    Kurtz, C.B.2    Macdougall, J.E.3
  • 24
    • 60749099506 scopus 로고    scopus 로고
    • Pilot study on the effect of linaclotide in patients with chronic constipation
    • Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gas-troenterol. 2009;104:125-132.
    • (2009) Am J Gas-troenterol , vol.104 , pp. 125-132
    • Johnston, J.M.1    Kurtz, C.B.2    Drossman, D.A.3
  • 25
    • 78649690668 scopus 로고    scopus 로고
    • Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation
    • Johnston JM, Kurtz CB, MacDougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010;139:1877-1886.
    • (2010) Gastroenterology , vol.139 , pp. 1877-1886
    • Johnston, J.M.1    Kurtz, C.B.2    Macdougall, J.E.3
  • 26
    • 77956258377 scopus 로고    scopus 로고
    • Effect of linaclotide on IBS-C symptoms in the flrst week of treatment: Results from a phase 2B study [AGA abstract 157]
    • Lembo AJ, Johnston JM, Lavins BJ, et al. Effect of linaclotide on IBS-C symptoms in the flrst week of treatment: results from a phase 2B study [AGA abstract 157]. Gastroenterology. 2009(suppl);136:A30-A31.
    • (2009) Gastroenterology , vol.136 , Issue.SUPPL.
    • Lembo, A.J.1    Johnston, J.M.2    Lavins, B.J.3
  • 27
    • 79953307643 scopus 로고    scopus 로고
    • Global end points in IBS clinical trials: Results from a phase 2B study of linaclotide [AGA abstract 236]
    • Johnston JM, MacDougall JE, Lavins BJ, et al. Global end points in IBS clinical trials: results from a phase 2B study of linaclotide [AGA abstract 236]. Gastroenterology. 2009 (suppl);136:A45-A46.
    • (2009) Gastroenterology , vol.136 , Issue.SUPPL.
    • Johnston, J.M.1    Macdougall, J.E.2    Lavins, B.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.